The MES GBM subtype, which is associated with a more aggressive phenotype and poorer prognosis, shows elevated expression of NF-κB target genes and upstream activators such as TNF-α, RELB, and TRADD, compared to other subtypes [37,38]. The gene discussed is NFKB1; the disease is glioblastoma.